

Macular Degeneration Guideline Committee – development

Date: 6th and 7th December 2016

Location: NICE offices, Manchester

Minutes: Final

Committee members present:		
	Day 1	Day 2
Waqaar Shah (Chair)	Present for all items	Present for all items
Katy Barnard (KB)	Present for all items	Present for all items
Nick Beare (NB)	Present for all items	Present for all items
Cathie Burke (CB)	Apologies	Present for all items
Jennifer Evans (JE)	Present for all items	Present for all items
Mary Freeman (MF)	Present for all items	Present for all items
Alexander Foss (AF)	Present for all items	Present for all items
Carol McCletchie (CM)	Present for all items	Present for all items
Ellen Rules (ER)	Present for all items	Apologies
Mary-Ann Sherratt (MS)	Present for all items	Apologies
Elizabeth Wick (EW)	Present for all items	Present from item 2
Cathy Yelf (CY)	Present for all items	Present for all items

In attendance:		
	Day 1	Day 2
Andrew Gyton (AG)	Present for all	Apologies

Macular Degeneration Guideline Committee 11 minutes

Commissioning Manager	items	
Sue Ellerby (SE) ICG – Clinical Advisor	Present for all items	Present for all items
Jamie Elvidge (JE) ICG – Technical Analyst (HE)	Present for all items	Present for all items
Gareth Haman (GH) NICE – Medical Editor	Present for items 1 to 3	Apologies
Marie Harrisingh (MH) ICG – Technical Analyst	Apologies	Present until end of item 3
Lesley Hayes NICE – Business Analyst	Apologies	Present for all items
Jane Lynn (JL) NICE – Business Analyst	Present for all items	Apologies
Vonda Murray (VM) ICG – Project Manager	Present for all items	Present for all items
Dave Nicholls (DN) NICE – Information Specialist	Present for all items	Present for all items
Gabriel Rogers (GR) ICG – Technical Advisor (HE)	Present for all items	Apologies
Sue Spiers (SS) NICE – ICG, Associate Director	Apologies	Present for all items
Yingying Wang (YW) ICG – Technical Analyst	Present for all items	Present for all items

Observers:	Day 1	Day 2
Jean Bennie NICE – Technical Analyst	Present for all items	Apologies
Olivia Crane NICE – Technical Analyst	Present for all items	Present for items 2 to 4
Judith Hughes- PhD student	Present for all items	Present for all items

Attendees sending apologies for both Day 1 and Day 2:	
Louisa Crossley	NICE – Senior Medicines Advisor

Andy Charley	Committee member
--------------	------------------

DAY 1

**Item 1.
Introductions, apologies, minutes, DOI and objectives for the meeting**

The Chair welcomed the Committee members, attendees and observers to day 1 of the 11th Guideline Committee meeting for age-related macular degeneration (AMD).

Apologies were noted, as recorded above.

The Chair invited each attendee to declare any new conflicts since the previous meeting. The following conflicts were noted;

Attendee	Declaration	Action
Waqaar Shah	Chaired an education session for GP's on Ophthalmology (no payment received)	Declare and participate
Mary-Ann Sherratt	Attended a diabetic retinopathy education event in November. The event was sponsored by Bayer.	Declare and participate
Elizabeth Wick	In January 2017 to speak at a RCGP event, arranged by the RNIB. The talk is to a group of GP's about living with sight loss from a patient viewpoint	Declare and participate

The minutes were reviewed from GComm 10; 5th and 6th December. One correction was noted;

- Page 5, item 2 change the word option to optician

Subject to the amendment noted above the minutes were agreed to be an accurate record.

Item 2. Information for the public

GH talked about the various versions of the guideline that NICE publishes, and how the editor can support the committee in their work.

Item 3. RQ10) What is the effectiveness of treatment of neovascular AMD in people presenting with visual acuity better than 6/12?

RQ25) What is the effectiveness of treatment of neovascular AMD in people presenting with visual acuity worse than 6/96?

- Presentation of clinical evidence
- Presentation of published health economic evidence
- Agree evidence statements

YW presented evidence on what is the effectiveness of treatment of neovascular AMD in people presenting with visual acuity better than 6/12 and worse than 6/96. Evidence statements were agreed. JE presented the published health economic evidence.

Item 4. RQ12) What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?

RQ18) What is the effectiveness of different frequencies of administration for anti-VEGF regimens for the treatment of neovascular AMD?

Presentation of additional published health economic evidence

JE presented additional published health economic evidence for the effectiveness of different anti-angiogenic therapies or PDT for the treatment of neovascular AMD.

Item 5 RQ10) What is the effectiveness of treatment of neovascular AMD in people presenting with visual acuity better than 6/12?

RQ12) What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?

RQ14) What factors indicate that treatment for neovascular AMD should be stopped?

RQ18) What is the effectiveness of different frequencies of administration

for anti-VEGF regimens for the treatment of neovascular AMD?

RQ25) What is the effectiveness of treatment of neovascular AMD in people presenting with visual acuity worse than 6/96?

Original health economic model

JE and GR presented the economic model developed to provide evidence for all of the above review questions.

Item 6 RQ10, RQ12, RQ14, RQ18, RQ25 continued

Agree recommendations

The committee declined to make any recommendations, and this item was deferred to the next meeting, GComm12

Item 7 RQ7) What is the effectiveness of strategies to reduce the risk of developing AMD in the unaffected eye or slow the progression of AMD?

Review and finalise recommendations

Item 8 Brought forward from day 2 of the meeting (item 5)

YW provided an overview of the evidence presented for effectiveness of strategies to reduce the risk of developing AMD in the unaffected eye or slow the progression of AMD. The committee reviewed and agreed the recommendations.

Item 9.

Any other business

None

Item 10.

Summary and next steps

The Chair explained to the committee that an additional meeting would be scheduled for next year, and the post consultation meeting would be rearranged. The Chair briefly summarised the discussions from the meeting before closing day 1.

DAY 2

Item 1.

Introductions, apologies, DOI and objectives for the meeting

The Chair welcomed the Committee members, attendees and observers to day 2 of the 11th Guideline Committee meeting on age-related macular degeneration (AMD).

Apologies were noted, as recorded above.

The Chair invited each attendee to declare any new conflicts. No new conflicts were declared.

Having reviewed all previous and current declarations of interest it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

Item 2.

RQ9) What is the effectiveness of support strategies for people with visual impairment and AMD (for example reablement services and strategies for optimising existing visual performance)?

- Presentation of clinical evidence
- Agree evidence statements
- Recommendations

Item 3 was moved to become item 2

RQ3) What information do people with suspected or confirmed AMD and their family members or carers find useful, and in what format (for example written or oral), and when?

Recap - **RQ17)** What are the barriers and facilitators to appointment attendance and uptake of treatment for people with AMD?

- Presentation of clinical evidence
- Agree evidence statements

MH presented the evidence on what information do people with suspected or confirmed AMD and their family members or carers find useful, and in what format, and when. A recap of the evidence and recommendations from GComm 7 on what are the barriers and facilitators to appointment attendance and uptake of treatment for people with AMD.

Item 3.

RQ3) What information do people with suspected or confirmed AMD and

their family members or carers find useful, and in what format (for example written or oral), and when?

Recap - **RQ17)** What are the barriers and facilitators to appointment attendance and uptake of treatment for people with AMD?

- Presentation of clinical evidence
- Agree evidence statements

Item 2 was moved to become item 3

RQ9) What is the effectiveness of support strategies for people with visual impairment and AMD (for example reablement services and strategies for optimising existing visual performance)?

- Presentation of clinical evidence
- Agree evidence statements
- Recommendations

YW presented the evidence on, the effectiveness of support strategies for people with visual impairment and AMD. The committee discussed the evidence and made recommendations including a research recommendation.

Item 4.

RQ3) What information do people with suspected or confirmed AMD and their family members or carers find useful, and in what format (for example written or oral), and when? – continued

- Agree recommendations

The committee discussed the evidence and made recommendations including a research recommendation.

Item 5.

RQ7) What is the effectiveness of strategies to reduce the risk of developing AMD in the unaffected eye or slow the progression of AMD?

Review and finalise recommendations

Item 5 Brought forward to day 1 (item 7)

Macular Degeneration Guideline Committee 11 minutes

Item 6. Recap

The recommendations made to date were reviewed and updated, where the Committee felt that a revision was appropriate, having come further in the guideline development process

Item 7. Any other business

None

Item 8. Summary and next steps

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

Date of next meeting:	GDG 12 - Thursday 5th January 2017
Location of next meeting:	NICE offices, Manchester